Audentes Therapeutics Inc (BOLD) Shares Sold by Fmr LLC

Share on StockTwits

Fmr LLC lowered its stake in shares of Audentes Therapeutics Inc (NASDAQ:BOLD) by 19.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 3,151,884 shares of the biotechnology company’s stock after selling 744,507 shares during the period. Fmr LLC owned approximately 0.07% of Audentes Therapeutics worth $67,198,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. NumerixS Investment Technologies Inc boosted its stake in Audentes Therapeutics by 1,200.0% during the 4th quarter. NumerixS Investment Technologies Inc now owns 1,300 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 1,200 shares during the last quarter. Amundi Pioneer Asset Management Inc. acquired a new position in Audentes Therapeutics during the 4th quarter valued at about $92,000. Great West Life Assurance Co. Can boosted its stake in Audentes Therapeutics by 96.0% during the 4th quarter. Great West Life Assurance Co. Can now owns 4,726 shares of the biotechnology company’s stock valued at $97,000 after purchasing an additional 2,315 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in Audentes Therapeutics by 46.1% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,280 shares of the biotechnology company’s stock valued at $138,000 after purchasing an additional 1,983 shares during the last quarter. Finally, Legal & General Group Plc boosted its stake in Audentes Therapeutics by 34.5% during the 4th quarter. Legal & General Group Plc now owns 6,632 shares of the biotechnology company’s stock valued at $141,000 after purchasing an additional 1,700 shares during the last quarter.

In related news, CEO Matthew R. Patterson sold 21,000 shares of the company’s stock in a transaction that occurred on Monday, February 25th. The stock was sold at an average price of $30.00, for a total value of $630,000.00. Following the transaction, the chief executive officer now owns 135,700 shares in the company, valued at $4,071,000. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Suyash Prasad sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, February 25th. The shares were sold at an average price of $30.06, for a total value of $300,600.00. Following the completion of the transaction, the vice president now owns 28,236 shares in the company, valued at approximately $848,774.16. The disclosure for this sale can be found here. In the last quarter, insiders sold 51,000 shares of company stock worth $1,650,600. 6.60% of the stock is owned by company insiders.

Shares of NASDAQ BOLD opened at $40.44 on Tuesday. Audentes Therapeutics Inc has a twelve month low of $17.95 and a twelve month high of $46.18. The company has a market capitalization of $1.72 billion, a PE ratio of -11.89 and a beta of 1.95.

Audentes Therapeutics (NASDAQ:BOLD) last announced its earnings results on Wednesday, February 27th. The biotechnology company reported ($0.84) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.08. During the same period in the previous year, the company posted ($0.82) earnings per share. As a group, research analysts forecast that Audentes Therapeutics Inc will post -3.83 earnings per share for the current fiscal year.

BOLD has been the topic of a number of research analyst reports. BidaskClub upgraded Audentes Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, February 23rd. ValuEngine upgraded Audentes Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Monday, April 1st. Zacks Investment Research downgraded Audentes Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, March 1st. HC Wainwright restated a “buy” rating and issued a $33.00 target price on shares of Audentes Therapeutics in a research note on Friday, January 11th. Finally, Mizuho restated a “buy” rating and issued a $45.00 target price on shares of Audentes Therapeutics in a research note on Friday, February 1st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $37.08.

COPYRIGHT VIOLATION NOTICE: “Audentes Therapeutics Inc (BOLD) Shares Sold by Fmr LLC” was first posted by Macon Daily and is owned by of Macon Daily. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://macondaily.com/2019/04/16/audentes-therapeutics-inc-bold-shares-sold-by-fmr-llc.html.

About Audentes Therapeutics

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

See Also: Front-End Load

Want to see what other hedge funds are holding BOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Audentes Therapeutics Inc (NASDAQ:BOLD).

Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.